Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives $15.50 Average Target Price from Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.50.

Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Achieve Life Sciences in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Friday, March 27th.

Achieve Life Sciences Stock Performance

Shares of Achieve Life Sciences stock opened at $3.14 on Monday. The stock’s fifty day simple moving average is $4.15 and its 200 day simple moving average is $4.29. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $167.14 million, a PE ratio of -2.42 and a beta of 1.96. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $6.03.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). On average, research analysts predict that Achieve Life Sciences will post -1.17 EPS for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in Achieve Life Sciences during the 1st quarter worth about $32,000. Next Capital Management LLC acquired a new position in shares of Achieve Life Sciences during the third quarter worth about $51,000. Sender Co & Partners Inc. acquired a new position in shares of Achieve Life Sciences during the second quarter worth about $56,000. OneDigital Investment Advisors LLC bought a new position in shares of Achieve Life Sciences during the third quarter worth about $63,000. Finally, Magnolia Capital Advisors LLC bought a new position in shares of Achieve Life Sciences during the fourth quarter worth about $64,000. 33.52% of the stock is owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.